HealthQuill clinical trial
The UK’s Medicines and Healthcare products Regulatory Agency has approved Janssen-Cilag Limited’s guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis.
Drugs Health Pharma

UK clears Janssen-Cilag’s drug for Crohn’s disease, ulcerative colitis

HQ Team May 19, 2025: The UK’s Medicines and Healthcare products Regulatory Agency has approved Janssen-Cilag Limited’s guselkumab (Tremfya) to treat Crohn’s disease.

Read More
Bristol Myers Squibb’s end-phase trial to test a drug for treating a heart condition, where the muscle of the heart's main pumping chamber becomes abnormally thickened, has failed to meet its goals.
Drugs Health Medical

Bristol Myers’ test drug to treat a type of heart disease fails to meet goals

HQ Team April 15, 2025: Bristol Myers Squibb’s end-phase trial to test a drug for treating a heart condition, where the muscle of.

Read More
United Therapeutics Corporation, a public benefit corporation, got approval from US regulators to start a clinical trial for organ transplantation from genetically modified pigs to treat kidney disease.
Drugs Health Medical

US regulator approves pig organ transplant trial to treat kidney disease 

United Therapeutics Corporation, a public benefit corporation, got approval from US regulators to start a clinical trial for organ transplantation from genetically modified.

Read More
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from the Japanese company.
Drugs Health Pharma

Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million

Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.

Read More
Drugs Health Pharma

Ketamine pill may revolutionize treatment for hard-to-treat depression

HQ Team October 25,  2024: A recent study indicates that a new slow-release ketamine pill could offer a promising alternative for individuals suffering.

Read More
British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a standard-of-care combination, according to the company.
Drugs Health Medical

New CAR T-cell therapy offers hope for children with aggressive blood cancer

HQ Team October 14, 2024: Children with aggressive blood cancer may soon have access to a new treatment, CAR T-cell therapy, targeting T-cell.

Read More
Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an upfront payment of $850 million.
Drugs Health Pharma

Roche arm to buy breast cancer portfolio from Regor for $850 million

Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an.

Read More
Shanghai Henlius Biotech, Inc., and US-based Organon & Co. announced their end-stage trial for investigational breast cancer had met its main goal of an absence of cancer in treated patients.
Drugs Health Pharma

Henlius, Organon trial drug meets goal of an absence of breast cancer

Shanghai Henlius Biotech, Inc., and US-based Organon & Co. announced their end-stage trial for investigational breast cancer had met its main goal of.

Read More
Drugs Health Medical

Breakthrough gene therapy restores hearing in children with inherited deafness

HQ Team August15, 2024: A clinical trial has successfully restored hearing in five children suffering from inherited deafness by administering gene therapy to.

Read More
The US-based Merck and Co.’s investigational medicine to protect infants from respiratory syncytial virus (RSV) disease has resulted in lowering infections, according to the company.
Drugs Health Pharma

Merck’s experimental RSV injection lowers infections in infants 

The US-based Merck and Co.’s investigational medicine to protect infants from respiratory syncytial virus (RSV) disease has resulted in lowering infections, according to.

Read More